Fig. 1: Response to venetoclax. | Blood Cancer Journal

Fig. 1: Response to venetoclax.

From: Venetoclax for the treatment of translocation (11;14) AL amyloidosis

Fig. 1

Case numbers are displayed on the Y-axis. CR complete response, MRD minimal residual disease, NE not evaluable, NR no response, VGPR very good partial response, Ven venetoclax, d dexamethasone, VenBd venetoclax, bortezomib, and dexamethasone, VenBRd venetoclax, bortezomib, lenalidomide and dexamethasone, VenBCd venetoclax, bortezomib, cyclophosphamide and dexamethasone.

Back to article page